HBM Healthcare Investments — Full Portfolio
7 tracked investments · listed companies and verified rows first
HealthtechMaple Grove, US
Tom Ressemann(Executive Officer, Director)
BoardMichael Liang(Director)Robert Weisskoff(Director)inDan Sachs(Director)
Co-investorsF-Prime CapitalBaird CapitalLongitude Capital
Healthcare company acquired by Mirum Pharmaceuticals, a former RiverVest portfolio company.
San Mateo, US
Keting Chu(Executive Officer, Director)Dajun Yang(Director)Nancy Hong(Director)Alon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsFrazier Life SciencesRA CapitalRiverVest Venture PartnersNovo HoldingsT. Rowe PriceWellington Management
Curevo Vaccine is a clinical-stage biotech company developing non-mRNA vaccines, with a lead adjuvanted subunit vaccine candidate (amezosvatein/CRV-101) for shingles and chickenpox.
BiotechHealthtech
Co-investorsAdjuvant CapitalOrbiMedRA CapitalSanofi VenturesJanus Henderson InvestorsMedicxi
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Executive Officer, Director)
BoardIvan Trifunovich(Director)John Wesley(Director)
Co-investors8VCAisling CapitalMission Bay CapitalMission BiocapitalOlive Tree CapitalSR One Capital Management+1 more
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investors5AM VenturesARCH Venture PartnersOUP (Osage University Partners)AlexandriaDeerfield Management CompanyMaverick Ventures+4 more
The page presents a biography of Dr.
Biotech
Co-investorsAvoro Capital AdvisorsEIR VenturesKurma PartnersRA CapitalSamsara BioCapitalSunstone Capital+2 more
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)Amy Bachrodt(Chief Financial Officer)Jeremy S. Caldwell(Executive Officer, Director)Chin Lee(Chief Medical Officer)Steve Staben(Chief Scientific Officer)Sofia Touami(Chief Business Officer)
Co-investorsREDMILEVersant VenturesBAM ElevateFranklin TempletonInvusJanus Henderson Investors+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.